Biodel Reports Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates

Biodel Inc. (Nasdaq:BIOD) today announced positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog-based formulations, BIOD-238 and BIOD-250, conducted to evaluate the pharmacokinetic and injection site toleration profiles relative to Humalog®, a rapid-acting insulin analog.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news